P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer.

Autor: Maynard JP; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Lu J; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Vidal I; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Hicks J; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Mummert L; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Ali T; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Kempski R; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Carter AM; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Sosa RY; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Peiffer LB; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Joshu CE; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Lotan TL; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.; Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., De Marzo AM; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.; Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Sfanos KS; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.; Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Publikováno v: The Journal of pathology [J Pathol] 2022 Feb; Vol. 256 (2), pp. 149-163. Date of Electronic Publication: 2021 Nov 25.

Preparation and preliminary evaluation of a tritium-labeled allosteric P2X4 receptor antagonist.

Autor: Nagel, Jessica, Törmäkangas, Olli, Kuokkanen, Katja, El-Tayeb, Ali, Messinger, Josef, Abdelrahman, Aliaa, Bous, Christiane, Schiedel, Anke C., Müller, Christa E.

Publikováno v: Purinergic Signalling; Dec2024, Vol. 20 Issue 6, p645-656, 12p

P2 purinergic receptor expression and function in tumor-related immune cells.

Autor: Manoharan V; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Adegbayi OO; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Maynard JP; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. maynard@jhmi.edu.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. maynard@jhmi.edu.

Publikováno v: Purinergic signalling [Purinergic Signal] 2024 Oct 10. Date of Electronic Publication: 2024 Oct 10.

Covalent functionalisation controlled by molecular design for the aptameric recognition of serotonin in graphene-based field-effect transistors.

Autor: Wetzl, Cecilia, Brosel-Oliu, Sergi, Carini, Marco, Di Silvio, Desiré, Illa, Xavi, Villa, Rosa, Guimera, Anton, Prats-Alfonso, Elisabet, Prato, Maurizio, Criado, Alejandro

Publikováno v: Nanoscale; 11/7/2023, Vol. 15 Issue 41, p16650-16657, 8p

P2 purinergic receptor dysregulation in urologic disease.

Autor: Maynard, Janielle P., Sfanos, Karen S.

Publikováno v: Purinergic Signalling; Sep2022, Vol. 18 Issue 3, p267-287, 21p